Drug intelligence / Profile preview

Xiaoer Liuwei Eczema Gel

Development stage: Phase 2
Lead developer: Shandong Hanfang Pharmaceutical
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Topical

Overview

Xiaoer Liuwei Eczema Gel (小儿六味湿疹凝胶) is a traditional Chinese medicine (TCM) Class 1.1 innovative drug co-developed by Suzhou Yusen New Drug Development and Shandong Hanfang Pharmaceutical. Formulated as a topical gel, it is designed to clear heat, dry dampness, dispel wind, and relieve itching (清热燥湿、祛风止痒). The drug is primarily developed for the treatment of mild-to-moderate atopic dermatitis (eczema) in children, specifically targeting the traditional Chinese medicine pattern of damp-heat accumulation. It is currently undergoing Phase II clinical evaluation in pediatric patients.

Other names: Xiaoer Liuwei Shizhen Ningjiao小儿六味湿疹凝胶

Beyond the preview

Go deeper on Xiaoer Liuwei Eczema Gel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiaoer Liuwei Eczema Gel.